Diabetes research and clinical practice
-
Diabetes Res. Clin. Pract. · Dec 2007
Recombinant human epidermal growth factor (REGEN-D 150): effect on healing of diabetic foot ulcers.
Recombinant human epidermal growth factor (REGEN-D 150), which was cloned and over expressed in E. coli, has shown enhanced healing of chronic diabetic foot ulcers (DFU) by significantly reducing the duration of healing in addition to providing excellent quality of wound healing and reepithelization. Post-marketing surveillance (PMS) study of REGEN-D 150 in 135 patients of DFU in India was compared with Phase III clinical trial data of REGEN-D 150 in India. Statistical analysis of study data determined that the empirical survival probability distribution, in terms of non-healing of ulcers, was lowest in the case of PMS study, better than that for Phase III; more DFU patients were healed in PMS study. ⋯ The average wound healing time was significantly lower in PMS study, 4.8 weeks, while it was 9 weeks in Phase III clinical trials while the average wound healing with REGEN-D 150 was found to be 86% in this study. REGEN-D 150 has been found to result in healthy granulation and stimulate epithelization, thus leading to final wound closure. The PMS study has established the efficacy of REGEN-D 150 in faster healing of diabetic foot ulcers.
-
Diabetes Res. Clin. Pract. · Dec 2007
Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in hospitalized patients with pneumonia.
Despite its ubiquitous use, the value of subcutaneous insulin-by-glucose sliding scales (SISS) for the management of in-patient hyperglycemia has not been carefully assessed. ⋯ Among patients admitted to a medical ward with pneumonia, an SISS is associated with higher glucose levels and poorer clinical outcomes.